CRISPR/Cas9 gene editing for curing sickle cell disease.

CRISPR/Cas9 gene editing for curing sickle cell disease.
复制标题

DOI:
10.1016/j.transci.2021.103060
复制
发表时间:
2021-03
期刊:
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
影响因子:
--
通讯作者:
Bao G
Bao G
中科院分区:
其他
文献类型:
--
作者:
Park SH;Bao G

文献摘要

参考文献

被引文献

相似文献

镰状细胞病(SCD)是最常见的单基因血液疾病,以剧烈疼痛、终末器官损害和早期死亡为特征。SCD的治疗选择仍然非常有限。只有四种FDA批准的药物可以减少急性并发症。SCD的唯一治疗方法是造血干细胞移植,通常来自匹配的亲属捐赠者。无论是否有合适的供者和移植物抗宿主病,在体外对自体造血干细胞和祖细胞进行工程,然后移植转基因细胞,可能会提供一种适用于所有患者的根治方法。本文综述了CRISPR/CAS9基因编辑技术在治疗SCD中的应用,包括对β-珠蛋白(HbB)中SCD突变的根治性纠正和诱导胎儿血红蛋白逆转镰状细胞的作用。我们总结了主要的成就和挑战,旨在为基于基因编辑的方法在治疗SCD方面的潜力提供一个更清晰的视角。
Sickle cell disease (SCD) is the most common monogenic blood disorder marked by severe pain, end-organ damage, and early mortality. Treatment options for SCD remain very limited. There are only four FDA approved drugs to reduce acute complications. The only curative therapy for SCD is hematopoietic stem cell transplantation, typically from a matched, related donor. Ex vivo engineering of autologous hematopoietic stem and progenitor cells followed by transplantation of genetically modified cells potentially provides a permanent cure applicable to all patients regardless of the availability of suitable donors and graft-vs-host disease. In this review, we focus on the use of CRISPR/Cas9 gene-editing for curing SCD, including the curative correction of SCD mutation in β-globin (HBB) and the induction of fetal hemoglobin to reverse sickling. We summarize the major achievements and challenges, aiming to provide a clearer perspective on the potential of gene-editing based approaches in curing SCD.
DOI: 10.1016/j.celrep.2016.09.092
发表时间: 2016-10-25
期刊: Cell reports
影响因子: 8.8
作者:
Gundry MC;Brunetti L;Lin A;Mayle AE;Kitano A;Wagner D;Hsu JI;Hoegenauer KA;Rooney CM;Goodell MA;Nakada D
通讯作者: Nakada D
DOI: 10.1101/gr.162339.113
发表时间: 2014-01
期刊: Genome research
影响因子: 7
作者:
Cho SW;Kim S;Kim Y;Kweon J;Kim HS;Bae S;Kim JS
通讯作者: Kim JS
DOI: 10.1038/nprot.2017.143
发表时间: 2018-03
期刊: Nature protocols
影响因子: 14.8
作者:
Bak RO;Dever DP;Porteus MH
通讯作者: Porteus MH
DOI: 10.1038/nbt.3290
发表时间: 2015-09
影响因子: 46.9
作者:
Hendel A;Bak RO;Clark JT;Kennedy AB;Ryan DE;Roy S;Steinfeld I;Lunstad BD;Kaiser RJ;Wilkens AB;Bacchetta R;Tsalenko A;Dellinger D;Bruhn L;Porteus MH
通讯作者: Porteus MH
DOI: 10.1016/j.tibtech.2013.04.004
发表时间: 2013-07
影响因子: 17.3
作者:
Gaj, Thomas;Gersbach, Charles A.;Barbas, Carlos F., III
通讯作者: Barbas, Carlos F., III